chr22-46353829-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_018006.5(TRMU):c.835G>A(p.Val279Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000206 in 1,614,010 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.00013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00021 ( 0 hom. )
Consequence
TRMU
NM_018006.5 missense
NM_018006.5 missense
Scores
9
9
1
Clinical Significance
Conservation
PhyloP100: 9.05
Genes affected
TRMU (HGNC:25481): (tRNA mitochondrial 2-thiouridylase) This nuclear gene encodes a mitochondrial tRNA-modifying enzyme. The encoded protein catalyzes the 2-thiolation of uridine on the wobble positions of tRNA(Lys), tRNA(Glu), and tRNA(Gln), resulting in the formation of 5-taurinomethyl-2-thiouridine moieties. Mutations in this gene may cause transient infantile liver failure. Polymorphisms in this gene may also influence the severity of deafness caused by mitochondrial 12S ribosomal RNA mutations. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 22-46353829-G-A is Pathogenic according to our data. Variant chr22-46353829-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 30819.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-46353829-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TRMU | NM_018006.5 | c.835G>A | p.Val279Met | missense_variant | 8/11 | ENST00000645190.1 | NP_060476.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TRMU | ENST00000645190.1 | c.835G>A | p.Val279Met | missense_variant | 8/11 | NM_018006.5 | ENSP00000496496.1 |
Frequencies
GnomAD3 genomes AF: 0.000131 AC: 20AN: 152210Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
20
AN:
152210
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000167 AC: 42AN: 251408Hom.: 0 AF XY: 0.000206 AC XY: 28AN XY: 135904
GnomAD3 exomes
AF:
AC:
42
AN:
251408
Hom.:
AF XY:
AC XY:
28
AN XY:
135904
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000214 AC: 313AN: 1461682Hom.: 0 Cov.: 30 AF XY: 0.000221 AC XY: 161AN XY: 727132
GnomAD4 exome
AF:
AC:
313
AN:
1461682
Hom.:
Cov.:
30
AF XY:
AC XY:
161
AN XY:
727132
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000131 AC: 20AN: 152328Hom.: 0 Cov.: 33 AF XY: 0.000161 AC XY: 12AN XY: 74488
GnomAD4 genome
AF:
AC:
20
AN:
152328
Hom.:
Cov.:
33
AF XY:
AC XY:
12
AN XY:
74488
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
22
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins Pathogenic:7
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 31, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Apr 22, 2024 | Criteria applied: PM3_VSTR,PS3_MOD,PM2_SUP,PP3 - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Aug 07, 2017 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2011 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centogene AG - the Rare Disease Company | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 26, 2022 | Variant summary: TRMU c.835G>A (p.Val279Met) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00017 in 251408 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in TRMU causing Transient, Acute Infantile Liver Failure (0.00017 vs 0.0011), allowing no conclusion about variant significance. c.835G>A has been reported in the literature in multiple compound heterozygous individuals affected with Transient, Acute Infantile Liver Failure (example: Zeharia_2009, Uusimaa_2011, Gaignard_2013, Grover_2015, Nicastro_2019). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five ClinVar submitters have assessed the variant since 2014: four classified the variant as likely pathogenic and one as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 28, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Alotaibi M et al. (2020) Discoveries Reports. 3 :e7 https://www.discoveriesjournals.org/discoveries-reports/DRep.2020.OACS-Alotaibi.pdf; This variant is associated with the following publications: (PMID: 21931168, 28562522, 19732863, 31980526, 34426522, 31589614, Alotaibi_2020_Article, 33083013, 33084218, 31160058, 23625533, 25665837, 38113276, 36939041, 33629572, 37272928) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 279 of the TRMU protein (p.Val279Met). This variant is present in population databases (rs387907022, gnomAD 0.06%). This missense change has been observed in individual(s) with acute infantile liver failure or infantile reversible respiratory chain deficiency (PMID: 19732863, 21931168, 23625533, 25665837). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 30819). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TRMU protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 22, 2015 | - - |
Aminoglycoside-induced deafness Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 25, 2024 | - - |
Aminoglycoside-induced deafness;C3278664:Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 11, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D;D;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;H;H;.;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;.;D;.;.
REVEL
Pathogenic
Sift
Uncertain
D;.;D;.;.
Sift4G
Uncertain
D;.;D;.;.
Polyphen
D;D;D;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at